Dr. Reddy’s Laboratories Ltd (RDY) has released an update.
Dr. Reddy’s Laboratories Ltd., an Indian pharmaceutical giant, has inked an exclusive licensing agreement with Pharmazz, Inc. to launch the innovative drug Lyfaquin® (Centhaquine) for treating hypovolemic shock in India. This collaboration aspires to meet the critical unmet medical needs in the country and marks Dr. Reddy’s commitment to introduce novel molecules and advanced care therapies. Centhaquine is a first-of-its-kind resuscitative agent, expected to substantially improve patient outcomes in life-threatening conditions characterized by severe blood or fluid loss.
For further insights into RDY stock, check out TipRanks’ Stock Analysis page.
